Table 1.
Characteristics of studies included in review of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis
| Trial | No randomized | Longest follow-up (months) | TAVI valve | No of women (%) | Mean (SD) age (years) | Mean (SD) risk score* | No (%) of patients | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low risk (score <4%) | NYHA class III or IV | Diabetes | Atrial fibrillation | Kidney disease | COPD | |||||||
| STACCATO | 72 | 3 | Edwards SAPIEN balloon expanding | 49 (70.0) | 81.0 (4.0) | 3.3 (1.4) | NR | 34 (48.6) | 4 (5.7) | NR | NR | 2 (2.9) |
| US Pivotal | 795 | 36 | Medtronic CoreValve self expanding | 372 (46.8) | 83.4 (6.7) | 7.4 (3.1) | 75 (9.4) | 686 (86.3) | 308 (38.7) | 351 (44.3) | 100 (12.7) | 88 (11.1) |
| NOTION | 280 | 24 | Medtronic CoreValve self expanding | 131 (46.8) | 79.1 (4.8) | 3.0 (1.6) | ~230 (81.8) | 131 (46.8) | 54 (19.3) | 74 (26.7) | 3 (1.1) | 33 (11.8) |
| PARTNER 2A | 2032 | 24 | Edwards SAPIEN XT balloon expanding | 924 (45.5) | 81.6 (6.7) | 5.8 (2.0) | ~136 (6.7) | 1558 (76.7) | 730 (35.9) | 671 (33.0) | 104 (5.1) | 627 (30.9) |
NR=not reported; NYHA=New York Heart Association; COPD=chronic obstructive pulmonary disease.
*STS-PROM (Society of Thoracic Surgeons predicted risk of mortality) risk score.